Tejas Patil, MD

Looking toward the future management of solid tumors with NRG1 fusions, expert panelists consider how the availability of seribantumab therapy may impact their practice.

A brief review of key takeaways from the CRESTONE clinical trial of seribantumab therapy in solid tumors with NRG1 fusions.

Closing out their review of data from the CRESTONE clinical trial, expert panelists highlight the duration and depth of response with seribantumab therapy.

Shared insight on key efficacy data from the CRESTONE clinical trial of seribantumab therapy in solid tumors with NRG1 fusions.

Expert perspectives on the trial design of and safety data from CRESTONE, which analyzed seribantumab therapy in solid tumors with NRG1 fusions.

This article summarizes the key side effects associated with ADT for the treatment of prostate cancer and discusses strategies to optimize management.